Literature DB >> 16750329

Definition and delineation of the clinical target volume for rectal cancer.

Sarah Roels1, Wim Duthoy, Karin Haustermans, Freddy Penninckx, Vincent Vandecaveye, Tom Boterberg, Wilfried De Neve.   

Abstract

PURPOSE: Optimization of radiation techniques to maximize local tumor control and to minimize small bowel toxicity in locally advanced rectal cancer requires proper definition and delineation guidelines for the clinical target volume (CTV). The purpose of this investigation was to analyze reported data on the predominant locations and frequency of local recurrences and lymph node involvement in rectal cancer, to propose a definition of the CTV for rectal cancer and guidelines for its delineation. METHODS AND MATERIALS: Seven reports were analyzed to assess the incidence and predominant location of local recurrences in rectal cancer. The distribution of lymphatic spread was analyzed in another 10 reports to record the relative frequency and location of metastatic lymph nodes in rectal cancer, according to the stage and level of the primary tumor.
RESULTS: The mesorectal, posterior, and inferior pelvic subsites are most at risk for local recurrences, whereas lymphatic tumor spread occurs mainly in three directions: upward into the inferior mesenteric nodes; lateral into the internal iliac lymph nodes; and, in a few cases, downward into the external iliac and inguinal lymph nodes. The risk for recurrence or lymph node involvement is related to the stage and the level of the primary lesion.
CONCLUSION: Based on a review of articles reporting on the incidence and predominant location of local recurrences and the distribution of lymphatic spread in rectal cancer, we defined guidelines for CTV delineation including the pelvic subsites and lymph node groups at risk for microscopic involvement. We propose to include the primary tumor, the mesorectal subsite, and the posterior pelvic subsite in the CTV in all patients. Moreover, the lateral lymph nodes are at high risk for microscopic involvement and should also be added in the CTV.

Entities:  

Mesh:

Year:  2006        PMID: 16750329     DOI: 10.1016/j.ijrobp.2006.02.050

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  65 in total

1.  Treatment Intensification for Locally Advanced Rectal Cancer: Impact on Pathological Complete Response and Outcomes.

Authors:  Monica DI Tommaso; Consuelo Rosa; Luciana Caravatta; Antonietta Augurio; Valentina Borzillo; Sara DI Santo; Francesca Perrotti; Maria Taraborrelli; Roberta Cianci; Paolo Innocenti; Pierluigi DI Sebastiano; Antonella Colasante; Domenico Angelucci; Massimo Basti; Giulia Sindici; Lorenzo Mazzola; Giuseppe Pizzicannella; Nicola DI Bartolomeo; Michele Marchioni; Marta DI Nicola; Domenico Genovesi
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Laparoscopic salvage surgery for locally recurrent rectal cancer.

Authors:  Toshiya Nagasaki; Takashi Akiyoshi; Masashi Ueno; Yosuke Fukunaga; Satoshi Nagayama; Yoshiya Fujimoto; Tsuyoshi Konishi; Toshiharu Yamaguchi
Journal:  J Gastrointest Surg       Date:  2014-05-17       Impact factor: 3.452

3.  Radiation target volume definition after induction chemotherapy in locally advanced rectal cancer.

Authors:  Francesca De Felice; Daniela Musio; Vincenzo Tombolini
Journal:  Int J Colorectal Dis       Date:  2016-04-26       Impact factor: 2.571

4.  Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors.

Authors:  Sofia Conde; Margarida Borrego; Tânia Teixeira; Rubina Teixeira; Anabela Sá; Paula Soares
Journal:  Rep Pract Oncol Radiother       Date:  2012-08-21

5.  Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.

Authors:  Pei-Long Sun; Bing Li; Qi-Fa Ye
Journal:  Int J Colorectal Dis       Date:  2012-03-20       Impact factor: 2.571

6.  Intensity-modulated radiation therapy for pelvic oligo-recurrence from rectal cancer: long-term results from a single institution.

Authors:  Xiang-Gao Zhu; Yong-Heng Li; Xiao-Fan Li; Yong Cai
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

7.  Mapping of lateral pelvic lymph node recurrences in rectal cancer: a radiation oncologist's perspective.

Authors:  Seo Hee Choi; Jee Suk Chang; Hong In Yoon; Dong-Su Jang; Nam Kyu Kim; Joon Seok Lim; Byung So Min; Hyuk Huh; Sang Joon Shin; Joong Bae Ahn; Woong Sub Koom
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-15       Impact factor: 4.553

8.  Preoperative Chemoradiotherapy for Rectal Cancer in Patients Aged 75 Years and Older: Acute Toxicity, Compliance with Treatment, and Early Results.

Authors:  Valentine Guimas; Jihane Boustani; Benjamin Schipman; Nicolas Lescut; Marc Puyraveau; Jean François Bosset; Stéphanie Servagi-Vernat
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

9.  Diffusion-weighted MRI in locally advanced rectal cancer : pathological response prediction after neo-adjuvant radiochemotherapy.

Authors:  M Intven; O Reerink; M E P Philippens
Journal:  Strahlenther Onkol       Date:  2012-12-19       Impact factor: 3.621

Review 10.  Adjuvant and neoadjuvant chemoradiation or radiotherapy in rectal cancer--a review focusing on open questions.

Authors:  Lutz Moser; Jörg-Peter Ritz; Wolfgang Hinkelbein; Stefan Höcht
Journal:  Int J Colorectal Dis       Date:  2007-12-07       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.